{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Aerobic dance during chemotherapy in patients with breast cancer with cognitive impairment (ADANC): protocol for an assessor-blinded randomised clinical trial.","author":[{"@type":"Person","name":"Yuqi Cheng"},{"@type":"Person","name":"Lu Xu"},{"@type":"Person","name":"Nan Xia"},{"@type":"Person","name":"Jue Wang"},{"@type":"Person","name":"Weijuan Yang"},{"@type":"Person","name":"Cuifeng Jin"},{"@type":"Person","name":"Rongrong Wang"},{"@type":"Person","name":"Jianjie Qin"},{"@type":"Person","name":"Yi Zhu"}],"datePublished":"2025","isPartOf":{"@type":"Periodical","name":"BMJ open"},"identifier":"https://doi.org/10.1136/bmjopen-2024-092003","description":"\n Introduction\n Therapeutic exercise has been used to improve cancer-related dysfunction. Recent studies suggest that exercise after chemotherapy can improve cancer-related cognitive impairment. However, the effect of exercise during chemotherapy in patients with breast cancer remains unclear. Aerobic dance is a comprehensive form of aerobic exercise which may be more easily accepted by female patients. The Aerobic Dance Against NeuroCognitive decline (ADANC) trial is designed to evaluate the effectiveness of aerobic dance during chemotherapy on breast cancer-related cognitive impairment. It aims to determine if aerobic dance offers better cognitive improvement compared with brisk walking of equal training intensity.\n \n \n Methods and analysis\n Participants will be recruited from the First Affiliated Hospital of Nanjing Medical University and randomly assigned in a 1:1:1 ratio to either the aerobic dance group, the fast walking group or the usual care group. The aerobic dance and brisk walking groups will participate in supervised sessions lasting 50 min, three times a week for 12 weeks. The exercise intensity will be adjusted based on the rating of perceived exertion and heart rate before and after each session. Assessments will be conducted at baseline (T0), midway through the intervention (T1), at the end of the intervention (T2) and 12 weeks post-intervention (T3). The assessment will cover cognitive function, cancer-related fatigue, anxiety, depression, sleep quality, quality of life and anthropometric measurements, including arm volume. The main hypotheses are to assess the effectiveness of aerobic dance on chemotherapy-related cognitive impairment in patients with breast cancer and to determine if aerobic dance offers greater cognitive improvement compared with brisk walking of equivalent training intensity.\n \n \n Ethics and dissemination\n The trial was prospectively registered in the Clinical Trials Registry and received approval from the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (reference number: 2023-SR-732). The results will be disseminated through peer-reviewed publications and presentations at conferences. Only the principal investigators will have access to the final trial dataset, and the full protocol and anonymised participant-level dataset will be available on reasonable request.\n \n \n Trial registration number\n \n NCT06234150\n .\n \n ","url":"https://innscience.ca/en/community/literature/14159628-59b6-4982-847d-18422987f195"}